# Beth Devin

> Beth Devin is a Series A investor at HearstLab (San Francisco Bay Area) backing B2B and PaaS. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [HearstLab](https://shizune.co/investors/profile/hearstlab-36b3)
- Location: San Francisco Bay Area, United States
- Total investments: 1
- Last investment: Feb 2024
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/beth-devin/0/429/70a

Beth Devin is a Series A investor at HearstLab in San Francisco Bay Area focused on B2B and PaaS. Beth Devin is the managing director and head of Innovation Network & Emerging Technology at Citi Ventures.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| B2B | 1 | 100% |
| PaaS | 1 | 100% |
| SaaS | 1 | 100% |
| Software | 1 | 100% |
| Pharmaceutical | 1 | 100% |

6 industries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Strategikon Pharma | Clinical Maestro™ by Strategikon Pharma is the only commercially available software platform for the end- to- end management of “clinical business operations”, which is the pharmaceutical industry vertical for planning, outsourcing and budgeting clinical trials. Biopharmaceutical companies outsource 90% of their clinical development pipelinespending billions of dollars engaging in highly complex outsourced relationships with thousands of global service providers, each using their own processes, systems and reporting structures. These sophisticated relationships require complex outsourcing strategies, demanding clinical financial planning, extensive sourcing due diligence and rigorous performance management. Currently the industry manages these activities in Excel, using labor intensive, inefficient processes, costing billions of dollars in infrastructure costs, regulatory non-compliance fines and delays to market. Clinical Maestro takes a radically different approach to the management of clinical portfolio through a transformative redesign of Excel-driven processes into end-to-end integrated workflows, breaking the communication and data integration siloes between pharma companies and their outsourcing partners. Clinical Maestro™ cases studies with leading pharmaceutical companies and CROs demonstrate savings of >80% vs. manual processes, >95% prediction accuracy for clinical study budgets and high user satisfaction and engagement. | $7M | Series A | Feb 06, 2024 |  |

1 of 1 investments shown.

## Co-investors
- [Debiopharm Innovation Fund](https://shizune.co/investors/profile/debiopharm-innovation-fund) — VC Fund, 1 deal together
- [Golden Seeds](https://shizune.co/investors/profile/golden-seeds) — VC Fund, 1 deal together
- [Osage Venture Partners](https://shizune.co/investors/profile/osage-partners) — VC Fund, 1 deal together

## About HearstLab

VC Fund · New York, United States

HearstLab is an early-stage venture fund focused on women-led startups innovating across the enterprise technology, data analytics, health, fintech, transportation and media spaces. To date, HearstLab has invested in over 56 companies at the Seed and Series A stages, with four successful exits. The firm often participates as a co-investor and infollow-on rounds. HearstLab is a venture arm of the Hearst Corporation ("Hearst") and provides one year of services in addition to cash investments. With access to Hearst's resources across 360+ businesses, HearstLab’s breadth of services includes providing assistance with commercial deals, privacy and security, legal services, marketing support and raising capital. Portfolio companies also benefit from the strategic guidance and resource support of HearstLab Scouts, women leaders across Hearst who share their networks and expertise. HearstLab has a full-time dedicated team assisting with UI/UX, DevOps engineering, data security, data science, brand storytelling, financial modeling and business development.

5 contacts available at HearstLab.

| Name | Title | Profile |
| --- | --- | --- |
| Eve Burton | Co-Founder | https://shizune.co/investors/profile/eve-burton |
| Lisa Burton | Vice President | https://shizune.co/investors/profile/lisa-burton |
| Azahara Espejo | Director | https://shizune.co/investors/profile/azahara-garc%C3%ADa-espejo |
| Beth Devin | Scout, Investor & Advisor | https://shizune.co/investors/profile/beth-devin |
| Chris Wilkes | Vice President | https://shizune.co/investors/profile/chris-wilkes-891e |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Beth Devin invest in?

Beth Devin invests primarily in B2B, PaaS and SaaS startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Beth Devin last invest?

The most recent investment recorded for Beth Devin closed in Feb 2024. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co